Farkas' Departure a Positive for Sarepta (SRPT) Eteplirsen Approval - Oppenheimer
- Wall St. drops on bleak GE outlook; Microsoft blunts losses
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
- UPDATE: AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- General Electric (GE) Tops Q3 EPS by 2c; Updates FY16 EPS Outlook
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Oppenheimer's Sarepta Therapeutic (NASDAQ: SRPT) analyst Michelle Gilson said their checks suggest that Ronald Farkas, MD, PhD, has indeed left the FDA; additionally, he is no longer listed in the HHS employee directory.
They view this as a positive signal for eteplirsen approval, recalling Dr. Farkas was the team leader who led the review of eteplirsen, and was largely regarded as an antagonistic figure at eteplirsen's advisory committee in May.
Gilson notes the DMD community and experts were particularly inflamed by comments regarding patient effort in the trial and the review's treatment of the data set as if it were not from a rare disease setting.
Contrarily, they would have viewed a promotion for Farkas or departure of a more supportive figure (i.e., Woodcock) as a negative signal for eteplirsen approval.
The firm reiterated an Outperform rating and price target of $60 on SRPT.
Shares of Sarepta Therapeutic closed at $25.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Valeant's (VRX) Weak Business Could Force it to Refinance Debt - Wells Fargo's Maris
- PayPal (PYPL) PT Raised to $47 at Credit Suisse; Results Just 'Ok' But Visability Increases Conviction
- Jefferies Cuts Price Target on Reliance Steel (RS) Following 3Q EPS Miss and Guidance
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Hot Comments, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!